Cantab To Double R&D Facility
UK-based Cantab Pharmaceuticals has announced details of its new L10million ($15.8 million) R&D facility, which is to be constructed in Cambridge, England. L4.5 million is to be invested on fitting out specialist laboratories to facilitate the development of novel protein and virus-based immunotherapeutic products, through the use of its proprietary antigen and gene delivery systems.
Chief executive Jurek Sikorski said that the new building will enable the company to expand its staff to 200, and reflects the rapid growth of Cantab since it was established in 1989. The company's landlord, Trinity College, has agreed to contribute L1.5 million towards the cost of the project.
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
Free
7 day trial access
- All the news that moves the needle in pharma and biotech
- Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
- Receive The Pharma Letter daily news bulletin, free forever.
Become a subscriber
£820
Or £77 per month
- Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
- Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
- Daily roundup of key events in pharma and biotech.
- Monthly in-depth briefings on Boardroom appointments and M&A news.
- Choose from a cost-effective annual package or a flexible monthly subscription
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
Today's issue
Company Spotlight
Copyright © The Pharma Letter 2025 | Headless Content Management with Blaze